Predictions from a preclinical model: Studies of aromatase inhibitors and antiestrogens

Clinical Cancer Research

Volumn 9, Issue 1 II, 2003, Pages

  Brodie, Angela ^a   Jelovac, Danijela ^a   Long, Brian J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FULVESTRANT; LETROZOLE; MATRIGEL; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AROMATIZATION; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OVARIECTOMY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; AROMATASE; AROMATASE INHIBITORS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASMS, HORMONE-DEPENDENT; TUMOR CELLS, CULTURED;

EID: 0037241499     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Levenson, A. S., and Jordan, V. C. Selective estrogen receptor modulation. In: J. Pasqualini (ed.), Breast Cancer: Prognosis, Treatment and Prevention, pp. 271-280. New York: Marcel Dekker, 2002.
2. Brodie, A. Aromatase inhibitors and the application to the treatment of breast cancer. In: J. Pasqualini (ed.), Breast Cancer: Prognosis, Treatment and Prevention, pp 251-270. New York: Marcel Dekker, 2002.
3. Yue, W., and Brodie, A. M. H. A nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res., 54: 5092-5095, 1994.
4. Zhou, D., Pompon, D., and Chen, S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res., 50: 6949-6954, 1990.
5. Yue, W., Wang, J., Savinov, A., and Brodie, A. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res., 55: 3073-3077, 1995.
6. Lu, Q., Liu, Y., Long, B. J., Grigoryev, D., Gimbel, M., and Brodie, A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res. Treat., 57: 183-192, 1999.
7. Lu, Q., Yue, W., Wang, J., Liu, Y., Long, B., and Brodie, A. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology (Basel), 12 (Suppl. 5): 29-33, 1998.
8. Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Janicke, F., Pluzanska, A., Dank, M., Becquart, D., Bapsy, P. P., Salminen, E., Snyder, R., Lassus, M., Verbeek, J. A., Staffler, B., Chaudri-Ross, H. A., and Dugan, M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol., 19: 2596-2606, 2001.
9. Bonneterre, J., Thurlimann, B., Robertson, J. F., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., and von Euler, M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol., 18: 3748-3757, 2000.
10. Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., and von Euler, M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol., 18: 3758-3767, 2000.
11. Jones, S., Vogel, C., Arkhipov, A., Fehrenbacher, L., Eisenberg, P., Cooper, B., Honig, S., Polli, A., Whaley, F., diSalle, E., Tiffany, J., Consonni, A., and Miller, L. Multicenter, Phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J. Clin. Oncol., 17: 3418-3425, 1999.
12. Brodie, A., Lu, Q., Liu, Y., Long, B., Wang, J., and Yue, W. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology (Basel), 12 (Suppl. 5): 36-40, 1998.
13. The ATAC Trialists' Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the "Arimidex and Tamoxifen Alone or in Combination" (ATAC) trial. Br. J. Cancer, 85: 317-324, 2001.
14. Winer, E. P., Hudis, C., Bursein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., Braun, S., Cobleigh, M. A., Langer, A. S., Perotti, J., Powles, T. J., Whelan, T. J., and Browman, G. P. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J. Clin. Oncol., 20: 3317-3327, 2002.
15. Long, B., JeLovac, D., and Brodie, A. Breast Cancer Res. Treat., 69: 287, 2001.